The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Quartz on MSN20h
A new stronger Ozempic is coming. Here's what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
The rush for weight loss drugs like Wegovy and diabetes drugs like Ozempic (which is also used for weight loss) has drained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback